Stratec (SBS) Stock Overview
Provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
SBS Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Stratec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €16.92 |
| 52 Week High | €33.10 |
| 52 Week Low | €16.36 |
| Beta | 0.80 |
| 1 Month Change | -4.73% |
| 3 Month Change | -21.30% |
| 1 Year Change | -31.08% |
| 3 Year Change | -73.27% |
| 5 Year Change | -84.89% |
| Change since IPO | 225.20% |
Recent News & Updates
SBS: Rebased Fair Value And 2025 Margin Guidance Will Define Upside Potential
The analyst price target for Stratec has been cut from about €44.96 to €34.00, as analysts factor in updated fair value, discount rate, growth, margin, and P/E assumptions following recent target revisions from major banks. Analyst Commentary Recent research suggests that while headline price targets for Stratec have come down, some bullish analysts still see potential upside at current levels.
SBS: Future Upside Will Rely On Reset Margins And Higher P/E
Narrative Update on Stratec The updated analyst price target for Stratec is €28.46, reflecting recent target cuts of up to €12 from prior Street research as analysts factor in a slightly higher discount rate, modestly adjusted profit margin assumptions, and a higher future P/E multiple. Analyst Commentary Recent research commentary on Stratec has focused on recalibrating price targets while keeping an eye on execution risk and the valuation investors are being asked to pay.SBS: Future Upside Will Depend On Repriced Earnings Power And Margins
Analysts have trimmed their average price target for Stratec by around €2.40, with recent cuts to €34 helping to explain a slightly lower fair value estimate and modestly softer assumptions for growth, margins and future P/E. Analyst Commentary Recent research revisions on Stratec point to a reset in expectations, with lower price targets feeding into updated views on valuation, execution risk and growth assumptions.Recent updates
SBS: Rebased Fair Value And 2025 Margin Guidance Will Define Upside Potential
The analyst price target for Stratec has been cut from about €44.96 to €34.00, as analysts factor in updated fair value, discount rate, growth, margin, and P/E assumptions following recent target revisions from major banks. Analyst Commentary Recent research suggests that while headline price targets for Stratec have come down, some bullish analysts still see potential upside at current levels.SBS: Future Upside Will Rely On Reset Margins And Higher P/E
Narrative Update on Stratec The updated analyst price target for Stratec is €28.46, reflecting recent target cuts of up to €12 from prior Street research as analysts factor in a slightly higher discount rate, modestly adjusted profit margin assumptions, and a higher future P/E multiple. Analyst Commentary Recent research commentary on Stratec has focused on recalibrating price targets while keeping an eye on execution risk and the valuation investors are being asked to pay.SBS: Future Upside Will Depend On Repriced Earnings Power And Margins
Analysts have trimmed their average price target for Stratec by around €2.40, with recent cuts to €34 helping to explain a slightly lower fair value estimate and modestly softer assumptions for growth, margins and future P/E. Analyst Commentary Recent research revisions on Stratec point to a reset in expectations, with lower price targets feeding into updated views on valuation, execution risk and growth assumptions.
SBS: Higher Discount Rate And Index Removal Will Still Allow Future Upside
Narrative Update on Stratec The analyst price target for Stratec has been reduced by €1, as analysts reflect slightly adjusted assumptions around discount rates, revenue growth and profit margins in their updated models. Analyst Commentary Bearish analysts trimming their price targets, including the recent €1 reduction, are signaling a more cautious stance on Stratec.SBS: Higher Discount Rate Will Still Allow Future Upside Potential
Analysts have reduced their price target on Stratec by €1 to €26, reflecting updated assumptions regarding the company’s discount rate, revenue growth, profit margin and future P/E profile. Analyst Commentary Bearish analysts cutting the price target to €26 are signaling a more cautious stance on Stratec’s risk and reward trade off at current levels.SBS: Future Upside Will Rely On Earnings Power And Cost Controls
Narrative update on Stratec Analysts have trimmed their 12 month price target on Stratec by about €1, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research updates on Stratec point to a small pullback in published price targets, with a reduction of about €1 in the latest move and a prior cut from €30 to €27.SBS: Future Margin Recovery Will Rely On Efficiency Gains And Cost Controls
Analysts have trimmed their price target on Stratec, with the average moving slightly lower in line with a recent cut from €30 to €27, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research points to a more cautious stance on Stratec, with the reduced €27 price target reflecting updated views on what analysts see as fair value, the applied discount rate, revenue growth assumptions, margin profile and future P/E expectations.Returns On Capital Signal Tricky Times Ahead For Stratec (ETR:SBS)
Jan 10
SBS: Index Exit And 2025 Margin Guidance Will Define Upside Potential
Analysts have trimmed their fair value estimate for Stratec from about €51.00 to roughly €44.96. This aligns with a recent reduction in the Street price target to €27 from €30 as they factor in updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples.SBS: Margin Recovery Outlook Will Support Upside Despite Reduced Price Objective
Analysts have trimmed their price target on Stratec to EUR 27.00 from EUR 30.00, reflecting slightly more cautious assumptions on long term growth, a higher discount rate, and a modestly lower future P E multiple, despite marginally improved margin expectations. Analyst Commentary Bearish analysts have highlighted that the reduction in the price target to EUR 27.00 signals a more guarded stance on Stratec's medium to long term prospects, even as the rating on the shares remains unchanged at Hold.SBS: Future Margin Gains Will Emerge As Cost Controls Take Hold
Analysts have modestly reduced their price target on Stratec, trimming it by EUR 3 to EUR 27. This reflects slightly lower long term return expectations while maintaining a cautious stance on the shares.Stratec (ETR:SBS) Takes On Some Risk With Its Use Of Debt
Nov 29SBS: Margins Will Improve With Cost Management And Leadership Changes
The analyst price target for Stratec has been revised downward from €30 to €27. Analysts cited a slightly higher discount rate and modest changes in growth and profitability expectations as key drivers behind the adjustment.Stratec SE (ETR:SBS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 11Investors Give Stratec SE (ETR:SBS) Shares A 35% Hiding
Nov 07SBS: Future Leadership Will Drive Healthcare Diagnostics Forward Amidst Margin Pressures
Analysts have revised their price target for Stratec downward from €36.58 to €33.30, citing expectations of slower revenue growth and a slight decrease in profit margins. What's in the News Tanja Bücherl will join STRATEC SE's Board of Management as Chief Financial Officer effective November 1, 2025.Getting In Cheap On Stratec SE (ETR:SBS) Might Be Difficult
Sep 23Automation And Digitalization Will Transform Healthcare Diagnostics
Stratec’s consensus price target has been revised downward, primarily reflecting lowered forecasts for both revenue growth and net profit margin, resulting in a new fair value of €37.32. What's in the News Stratec increased its dividend to €0.60 per share for 2024 (previously €0.55), totaling €7.3 million to be distributed.An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 34% Undervalued
Jun 17Why We're Not Concerned About Stratec SE's (ETR:SBS) Share Price
Apr 25
Efficiency Measures And Acquisitions Like Natech Will Boost Future Market Presence
Efficiency measures and cost discipline initiatives could enhance net margins as market conditions stabilize.An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 42% Undervalued
Jan 18With A 25% Price Drop For Stratec SE (ETR:SBS) You'll Still Get What You Pay For
Nov 09Returns At Stratec (ETR:SBS) Appear To Be Weighed Down
Oct 26Here's Why It's Unlikely That Stratec SE's (ETR:SBS) CEO Will See A Pay Rise This Year
May 11Stratec's (ETR:SBS) Dividend Will Be Reduced To €0.55
Apr 11Stratec SE Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
Apr 01Stratec (ETR:SBS) Has Announced That Its Dividend Will Be Reduced To €0.55
Mar 28Is There An Opportunity With Stratec SE's (ETR:SBS) 36% Undervaluation?
Dec 21Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement
Nov 03We Think Stratec (ETR:SBS) Is Taking Some Risk With Its Debt
Oct 19Return Trends At Stratec (ETR:SBS) Aren't Appealing
Jul 12Stratec SE (ETR:SBS) Shares Could Be 43% Below Their Intrinsic Value Estimate
Jun 27Is Stratec (ETR:SBS) Using Too Much Debt?
May 25Stratec's (ETR:SBS) Upcoming Dividend Will Be Larger Than Last Year's
Apr 02Shareholder Returns
| SBS | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -8.9% | -1.8% | -0.9% |
| 1Y | -31.1% | -28.9% | -0.9% |
Return vs Industry: SBS underperformed the German Medical Equipment industry which returned -28.7% over the past year.
Return vs Market: SBS underperformed the German Market which returned 1.1% over the past year.
Price Volatility
| SBS volatility | |
|---|---|
| SBS Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: SBS has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SBS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 1,420 | Marcus Wolfinger | www.stratec.com |
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and integrating instrumentation and software.
Stratec SE Fundamentals Summary
| SBS fundamental statistics | |
|---|---|
| Market cap | €205.68m |
| Earnings (TTM) | -€242.00k |
| Revenue (TTM) | €250.86m |
0.8x
P/S Ratio-849.9x
P/E RatioIs SBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBS income statement (TTM) | |
|---|---|
| Revenue | €250.86m |
| Cost of Revenue | €186.64m |
| Gross Profit | €64.22m |
| Other Expenses | €64.46m |
| Earnings | -€242.00k |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 11, 2026
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 25.60% |
| Net Profit Margin | -0.097% |
| Debt/Equity Ratio | 0% |
How did SBS perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield47%
Payout RatioDoes SBS pay a reliable dividends?
See SBS dividend history and benchmarks| Stratec dividend dates | |
|---|---|
| Ex Dividend Date | Jun 24 2026 |
| Dividend Pay Date | Jun 26 2026 |
| Days until Ex dividend | 49 days |
| Days until Dividend pay date | 51 days |
Does SBS pay a reliable dividends?
See SBS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 12:46 |
| End of Day Share Price | 2026/05/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stratec SE is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Heider | Berenberg |
| Jan Koch | Deutsche Bank |
| Jan Koch | Deutsche Bank |